On ECHEMI
Home > Drugs > Zhejiang Hisun Pharmaceutical Co., Ltd.
Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Founded in:

    1998-02-11
  • Country:

    China China
  • Address:

    No. 46, Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province
  • Tax NO.:

    91330000704676287N
  • Registered Funds:

    1,207,873,716 yuan
  • Website:

  • Email:

Related Drugs
Aztreonam
Aztreonam
Name Description Content CAS NO. Registered Holders
Aztreonam

Extract from the above information

More

Extract from the above information

78110-38-0 31
Tolbutamide Tablets
Tolbutamide
Name Description Content CAS NO. Registered Holders
TOLBUTAMIDE

This product is a hypoglycemic drug. 1. It stimulates the pancreatic islet beta cells to secrete insulin, which presupposes that the islet beta cells also have a certain ability to synthesize and secrete insulin; 2. It inhibits liver glycogenolysis and gluconeogenesis by increasing portal vein insulin levels or directly acting on the liver, and reduces the generation and output of glucose in the liver; 3. It may also increase the sensitivity of extrapancreatic tissues to insulin and the utilization of sugar (probably mainly through post-receptor effects). Therefore, the overall effect is to reduce fasting blood sugar and postprandial blood sugar.

More

This product is a hypoglycemic drug. 1. It stimulates the pancreatic islet beta cells to secrete insulin, which presupposes that the islet beta cells also have a certain ability to synthesize and secrete insulin; 2. It inhibits liver glycogenolysis and gluconeogenesis by increasing portal vein insulin levels or directly acting on the liver, and reduces the generation and output of glucose in the liver; 3. It may also increase the sensitivity of extrapancreatic tissues to insulin and the utilization of sugar (probably mainly through post-receptor effects). Therefore, the overall effect is to reduce fasting blood sugar and postprandial blood sugar.

64-77-7 16
Zolmitriptan Tablets
Zolmitriptan
Name Description Content CAS NO. Registered Holders
Zolmitriptan

Zolmitriptan shows high affinity to human recombinant 5-HT1D and 5-HT1B receptors, and moderate affinity to 5-HT1A receptors. The N-desmethyl metabolite of this product also shows high affinity to 5-HT1B/1D receptors, and moderate affinity to 5-HT1A receptors. It is currently believed that the onset of migraine is related to local cranial vasodilation and/or the release of sensory neuropeptides (vasoactive intestinal peptide, substance P, calcitonin gene-related peptide) from nerve endings of the trigeminal nervous system. The therapeutic effect of this product on migraine may be through the stimulating effect on the 5-HT1B/1D receptors of intracranial blood vessels (including arteriovenous anastomoses) and sensory nerves of the trigeminal nervous system, resulting in cranial vasoconstriction and inhibition of the release of post-inflammatory neuropeptides.

More

Zolmitriptan shows high affinity to human recombinant 5-HT1D and 5-HT1B receptors, and moderate affinity to 5-HT1A receptors. The N-desmethyl metabolite of this product also shows high affinity to 5-HT1B/1D receptors, and moderate affinity to 5-HT1A receptors. It is currently believed that the onset of migraine is related to local cranial vasodilation and/or the release of sensory neuropeptides (vasoactive intestinal peptide, substance P, calcitonin gene-related peptide) from nerve endings of the trigeminal nervous system. The therapeutic effect of this product on migraine may be through the stimulating effect on the 5-HT1B/1D receptors of intracranial blood vessels (including arteriovenous anastomoses) and sensory nerves of the trigeminal nervous system, resulting in cranial vasoconstriction and inhibition of the release of post-inflammatory neuropeptides.

139264-17-8 38
Norfloxacin Tablets
Norfloxacin
Name Description Content CAS NO. Registered Holders
Norfloxacin

This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria. It acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death. It has effects on both Gram-positive and Gram-negative bacteria. Bacteria are not easy to develop resistance to this product, and there is no cross-resistance between similar drugs and antibiotics.

More

This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria. It acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death. It has effects on both Gram-positive and Gram-negative bacteria. Bacteria are not easy to develop resistance to this product, and there is no cross-resistance between similar drugs and antibiotics.

70458-96-7 35
Lansoprazole
Name Description Content CAS NO. Registered Holders
Lansoprazole

Extract from the above information

More

Extract from the above information

103577-45-3 88
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.